Sectors
As global AI capex surges, China's A-share tech manufacturers are posting massive profits. Fueled by upcoming 1.6T optical module shipments, New Easy East guided H1 profits up 102%, creating a gap for deeply discounted China AI stocks.
Sectors
Despite the July A-share tech sell-off, China's semiconductor sector is posting explosive earnings. Fueled by robust AI data-center demand, chip designer Yuanjie Technology guided H1 profits up 1,305%, creating a gap for cheap China AI stocks.
Sectors
On July 16, 2026, memory giant CXMT launched an $8B IPO on the STAR Market, the largest A-share IPO of 2026. Earmarking RMB 29.5B for DRAM and HBM projects, CXMT is positioned as a key bellwether for China's self-sufficient AI hardware thesis.
Market Brief
On July 16-17, 2026, 18 top firms filed for China's first Active ETFs with the CSRC. This regulatory milestone transforms the 6T-RMB A-share ETF market, providing daily transparency and real-time liquidity for global allocators.
Sectors
CXMT, China's largest DRAM maker, is preparing for a historic $9.8B IPO. Driven by the AI boom and US export controls, this listing offers global investors exposure to China's tech decoupling, balanced by persistent regulatory risks.
Sectors
As Chinese AI LLMs achieve technical parity with Western peers at 40-50% lower costs, Julius Baer has rated China tech overweight. Driven by the 15th Five-Year Plan, the A-share value chain offers secular growth at a deep valuation discount.
Valuation
China's AI industry has crossed the ¥1T threshold, growing over 30% in 2026. Driven by a potential $70B CapEx from ByteDance and strict localization mandates, a parallel, self-sufficient A-share AI hardware supply chain is emerging.
Sectors
Luxshare Precision priced its landmark Hong Kong H-share IPO at HKD 63.28, implying a historically tight ~13% AH discount. This compressed premium signals that global allocators are aggressively repricing China's high-tech manufacturing giants.
Sectors
Driven by the global AI infrastructure boom, northbound capital recorded a historic RMB 208.6B net inflow into A-shares in Q2 2026. Rather than chasing software, global allocators are aggressively buying deeply discounted hardware leaders.
Sectors
China's healthcare sector has rebounded 50% YTD in 2026, driven by global validation of its biotech assets. Highlighting this trend, AstraZeneca signed a landmark $1.74B siRNA deal with Shipharmaceuticals' subsidiary, Gigabio.
Sectors
China's memory chip sector is undergoing an earnings supercycle. Driven by robust AI demand and Samsung's planned 20% Q3 DRAM price hike, storage manufacturer Jiangbolong pre-announced a staggering H1 net profit surge of over 62,000% YoY.
Valuation
SASAC designated 28 SOEs as demonstration units for its world-class enterprise initiative. Their ~60 listed subsidiaries form a regulator-defined cohort—the cleanest starting universe to which the reform framework most directly applies. This installment maps and analyzes the list.